Global Streptococcus Infection Market – Industry Trends and Forecast to 2029

Global Streptococcus Infection Market, By Bacterial Type (Group A, Group B, Group C, Group D and Group G), Diagnosis (Antibody Test, Physical Examination, Throat culture and Others), Treatment (Antibiotics, Surgery and Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.

Streptococcus Infection Market Analysis and Size

The global streptococcus infection market is expected to witness significant growth during the forecast period.  Around 1 in 4 pregnant women carries or is colonized with group B streptococcus. According to WHO, group B streptococcus infection causes an estimated 150,000 preventable stillbirths and infant deaths each year. About 21.7 million pregnant women carry this bacteria, according to the first global study of group B strep.

 Data Bridge Market Research analyses a growth rate in the global streptococcus infection market in the forecast period 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Streptococcus Infection Market Scope and Segmentation

Market Definition

Streptococcus infections are the kind of bacterial infections that are caused by various strains of Streptococci bacteria. Numerous strains of streptococci can cause different types of infectious diseases such as strep throat, tonsillitis, blood infections, scarlet fever, pneumonia and others

Global Streptococcus Infection Market Dynamics

Drivers

• Rising Adoption of Antibiotics

Clostridium difficile infection is primarily associated with long-term antibiotic use. Increased antibiotic consumption changes the colon bacteria, allowing clostridium difficile bacteria to grow. Antibiotics such as penicillin or amoxicillin are more likely to cause streptococcus infection. The higher use of these antibiotics is increasing the prevalence of clostridium difficile infection, which is most likely to boost the demand for its treatments. Therefore, the more and more consumption of antibiotics acts as a major driver of growth in the global streptococcus infection market.

• Prevalence of streptococcus diseases

The rising incidence of this infection is boosting the growth of the market. For instance, a study by the London School of Hygiene and Tropical Medicine projected that out of 410,000 group B streptococcus cases each year, at least 147,000 stillbirths and infant deaths are projected to occur worldwide. Africa had the highest burden, with 54% of estimated cases and 65% of stillbirths and infant deaths. An increase in the prevalence of group B streptococcus infections and the rate of new infections is possible to drive the global streptococcus infection market.

Opportunities

• Rising Drug Development Activities

Higher drug development activities for developing and launching several new drugs are projected to create market opportunities for growth in the market by providing doctors with an alternate treatment option. Additionally, the development of a new class of non-antibiotic drugs and vaccines is most likely to open up a large number of opportunities for major market players while also increasing the competition for manufacturing better treatment options. Therefore, increased drug development activities for developing novel drugs for better treatment and prevention are anticipated to create market growth in the near future. For instance, in 2017, Pfizer started phase I/II trial of its group B streptococcus conjugate vaccine named PF-06760805, which incorporates at least five serotypes of group B streptococcus and could prevent around 95% of group B streptococcus disease in infants through maternal immunization.

• Increasing Demand for Retail Pharmacies

The rise in the number of these infectious therapeutics being delivered through retail pharmacies and the surge in the number of retail pharmacies in highly developed countries create much opportunities for the market growth. In addition, patients elect retail pharmacies to purchase drugs, as these are easily feasible.

 Restraints/Challenges

• Lack of skilled professionals

The lack of trained who cannot treat the patients with appropriate treatments could limit the growth of the global streptococcus infection market during a forecast period.

• High Cost For Drug Development

The current treatment options for streptococcus infection are limited to antibiotics, and numerous pharmaceutical companies are presently focusing on developing non-antibiotic alternatives. Developing a new class of drugs will offer many growth opportunities for key players, but it will also essentially require major investments in R&D activities of novel therapies. The significantly high investment requirements may act as an obstacle to market growth.  

This global streptococcus infection market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global streptococcus infection market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Streptococcus Infection Market       

COVID-19 has largely impacted and could continue to impact other companies' businesses, including their preclinical trials and clinical trials of microbiome-based therapeutics and diagnostic products. Although, with the relaxation of government restrictions associated with the pandemic and the occurrence of virtual clinical trials, R&D activities started their recovery since 2021.

Still, in the post-pandemic era, the biotechnology and pharmaceutical industries are expected to witness a huge growth in the future, as research and treatments are drifting toward normal patients again. Thus, this will significantly impact the global streptococcus infection market.

Global Streptococcus Infection Market Scope

The global streptococcus infection market is segmented on the basis of bacterial type, diagnosis, treatment, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Bacterial Type

• Group A
• Group B
• Group C
• Group D
• Group G

Diagnosis

• Antibody Test
• Physical Examination
• Throat culture
• Others

Treatment

• Antibiotics
• Surgery
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Global Streptococcus Infection Market Regional Analysis/Insights

The global streptococcus infection market is analyzed and market size insights and trends are provided by bacterial type, diagnosis, treatment, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global streptococcus infection market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has been witnessing a positive growth for global streptococcus infection market throughout the forecasted period due to latest technology development and the presence of variety of innovative drug molecule to enhance the treatment procedure.  

Asia-Pacific dominates the market due to increased prevalence of bacterial infections and increasing investment in healthcare infrastructure.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Streptococcus Infection Market Share Analysis

The global streptococcus infection market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global streptococcus infection market.

Key players operating in the global streptococcus infection market include:

• AstraZeneca (U.K.)
• Lilly (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• Novartis AG (Switzerland)
• Sun Pharmaceutical Industries Ltd. (India)
• Aurobindo Pharma (India)
• Lupin (India)
• Merck & Co., Inc. (U.S.)
• Pfizer Inc. (U.S.)
• GSK plc (U.K.)
• Hikma Pharmaceuticals PLC (U.K.)
• Cipla Inc. (India)
• Lupin (India)